NUTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

258.82M

+0.47%

5.557

-50.03%

252.54M

+19.24%

3.990

+55.86%

254.52M

+4.32%

3.850

-230.51%

Estimates Revision

The market is revising Upward the revenue expectations for Nutex Health Inc. (NUTX) for FY2025, with the revenue forecasts being adjusted by 16.89% over the past three months. During the same period, the stock price has changed by 77.58%.

Revenue Estimates for FY2025

Revise Upward

+16.89%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+188.32%

In Past 3 Month

Stock Price

Go Up

+77.58%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 265.00 USD with a low forecast of 230.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

230.00

Averages

265.00

High

300.00

Current: 0.000

Low

230.00

Averages

265.00

High

300.00

Maxim

Buy

downgrade

$225 -> $205

2025-08-26

Reason

Maxim

Price Target

$225 -> $205

2025-08-26

downgrade

Buy

Reason

Maxim lowered the firm's price target on Nutex Health to $205 from $225 and keeps a Buy rating on the shares. On August 14th, the company filed an NT 10-Q notification of inability to timely file its 10-Q for the three months ended 6/30/25, due to the incorrect accounting classification of certain non-cash obligations, the analyst tells investors in a research note. The firm views the accounting restatements, arbitration dynamics, and lawsuits against Nutex's primary arbitration vendor, HaloMD, as potential headwinds to the stock price, Maxim added.

Maxim

Buy

maintain

$100 -> $225

2025-05-20

Reason

Maxim

Price Target

$100 -> $225

2025-05-20

maintain

Buy

Reason

Benchmark

Buy

upgrade

$150 -> $300

2025-05-15

Reason

Benchmark

Price Target

$150 -> $300

2025-05-15

upgrade

Buy

Reason

Benchmark raised the firm's price target on Nutex Health to $300 from $150 and keeps a Buy rating on the shares based on "another big beat" in Q1 and positive updates to the firm's model. Based on greater visibility into the sustainability of rate arbitration success realization, the firm is "significantly lifting" its FY25 and FY26 outlooks for revenue, adjusted EBITDA and GAAP EPS, the analyst tells investors, adding that Nutex remains a "Benchmark Best Idea."

Maxim Group

Anthony Vendetti

Strong Buy

Maintains

$75 → $100

2025-04-08

Reason

Maxim Group

Anthony Vendetti

Price Target

$75 → $100

2025-04-08

Maintains

Strong Buy

Reason

Maxim raised the firm's price target on Nutex Health to $100 from $75 and keeps a Buy rating on the shares. The company delivered significantly better-than-expected Q4 results, driven largely by the company's success in achieving improved reimbursement by advancing claims through the No Surprises Act's IDR - independent dispute resolution - process, the analyst tells investors in a research note. Beyond IDR activity, Nutex continues to advance its core growth strategy, with its hospitals expanding service lines to treat higher-acuity patients and to drive increased inpatient and observation visit volumes, the firm adds.

Maxim Group

Anthony Vendetti

Strong Buy

Maintains

$50 → $75

2025-02-13

Reason

Maxim Group

Anthony Vendetti

Price Target

$50 → $75

2025-02-13

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Nutex Health Inc (NUTX.O) is 8.47, compared to its 5-year average forward P/E of -23.37. For a more detailed relative valuation and DCF analysis to assess Nutex Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-23.37

Current PE

8.47

Overvalued PE

72.86

Undervalued PE

-119.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

60.18

Current EV/EBITDA

3.97

Overvalued EV/EBITDA

168.96

Undervalued EV/EBITDA

-48.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.06

Current PS

1.02

Overvalued PS

10.25

Undervalued PS

-4.13

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NUTX News & Events

Events Timeline

No data

News

1.0

01-05Newsfilter

Nutex Health CEO to Present at 2026 J.P. Morgan Healthcare Conference

1.0

01-05PRnewswire

Nutex Health CEO to Present at 2026 J.P. Morgan Healthcare Conference

9.5

2025-12-31NASDAQ.COM

Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments

People Also Watch

Frequently Asked Questions

What is Nutex Health Inc (NUTX) stock price today?

The current price of NUTX is 184.11 USD — it has increased 3.38 % in the last trading day.

What is Nutex Health Inc (NUTX)'s business?

Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization (MSO), it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.

What is the price predicton of NUTX Stock?

What is Nutex Health Inc (NUTX)'s revenue for the last quarter?

Nutex Health Inc revenue for the last quarter amounts to 267.80M USD, increased 239.87 % YoY.

What is Nutex Health Inc (NUTX)'s earnings per share (EPS) for the last quarter?

Nutex Health Inc. EPS for the last quarter amounts to 7.76 USD, decreased -551.16 % YoY.

What changes have occurred in the market's expectations for Nutex Health Inc (NUTX)'s fundamentals?

How many employees does Nutex Health Inc (NUTX). have?

Nutex Health Inc (NUTX) has 800 emplpoyees as of January 09 2026.

What is Nutex Health Inc (NUTX) market cap?

Today NUTX has the market capitalization of 1.30B USD.